Cargando…

Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy

BACKGROUND: The aim of the current study was to evaluate oncologic outcomes of patients who were treated with salvage hysterectomy (HT), compared to systemic chemotherapy (CT) for persistent cervical cancer after definitive radiotherapy (RT)/ concurrent chemoradiotherapy (CCRT). METHODS: Patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takekuma, Munetaka, Takahashi, Fumiaki, Mabuchi, Seiji, Kudaka, Wataru, Horie, Koji, Ikeda, Mariko, Shikama, Ayumi, Mitsuhashi, Akira, Nagao, Shoji, Suzuki, Shiro, Mizuno, Mika, Nishio, Shin, Tokunaga, Hideki, Ota, Yukinobu, Kasamatsu, Takahiro, Kitagawa, Ryo, Toita, Takafumi, Kobayashi, Hiroaki, Ishikawa, Mitsuya, Yaegashi, Nobuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708164/
https://www.ncbi.nlm.nih.gov/pubmed/33256667
http://dx.doi.org/10.1186/s12885-020-07672-w
_version_ 1783617508407771136
author Takekuma, Munetaka
Takahashi, Fumiaki
Mabuchi, Seiji
Kudaka, Wataru
Horie, Koji
Ikeda, Mariko
Shikama, Ayumi
Mitsuhashi, Akira
Nagao, Shoji
Suzuki, Shiro
Mizuno, Mika
Nishio, Shin
Tokunaga, Hideki
Ota, Yukinobu
Kasamatsu, Takahiro
Kitagawa, Ryo
Toita, Takafumi
Kobayashi, Hiroaki
Ishikawa, Mitsuya
Yaegashi, Nobuo
author_facet Takekuma, Munetaka
Takahashi, Fumiaki
Mabuchi, Seiji
Kudaka, Wataru
Horie, Koji
Ikeda, Mariko
Shikama, Ayumi
Mitsuhashi, Akira
Nagao, Shoji
Suzuki, Shiro
Mizuno, Mika
Nishio, Shin
Tokunaga, Hideki
Ota, Yukinobu
Kasamatsu, Takahiro
Kitagawa, Ryo
Toita, Takafumi
Kobayashi, Hiroaki
Ishikawa, Mitsuya
Yaegashi, Nobuo
author_sort Takekuma, Munetaka
collection PubMed
description BACKGROUND: The aim of the current study was to evaluate oncologic outcomes of patients who were treated with salvage hysterectomy (HT), compared to systemic chemotherapy (CT) for persistent cervical cancer after definitive radiotherapy (RT)/ concurrent chemoradiotherapy (CCRT). METHODS: Patients with persistent cervical cancer treated with definitive RT/CCRT at 35 institutions from 2005 to 2014 were reviewed retrospectively (n = 317). Those who underwent a HT for persistent cervical cancer after definitive RT/CCRT were matched with propensity scores for patients who underwent systemic CT. Oncologic outcomes between the two groups using a propensity score matched–cohort analysis were compared. RESULTS: A total of 142 patients with persistent cervical cancer after definitive RT/CCRT were included after matching (HT: 71, systemic CT: 71). All background factors between HT and CT groups were well balanced. Median overall survival was 3.8 and 1.5 years in the HT and CT groups, respectively (p = 0.00193, hazards ratio [HR] 0.41, 95% confidence interval [CI] 0.23–0.73), Increasing residual tumor size was significantly associated with a high incomplete resection rate (p = 0.016, Odds Ratio 1.11, 95%CI 1.02–1.22). Severe late adverse events occurred in 7 patients (9.9%) in the HT cohort. CONCLUSION: The current study demonstrated that, when compared to systemic CT, the adoption of salvage HT for patients with persistent cervical cancer after definitive RT/CCRT reduced mortality rate by about 60%. This indicates that salvage HT could be curative treatment for those patients. Further prospective clinical trials with regard to salvage HT after RT/CCRT are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-020-07672-w.
format Online
Article
Text
id pubmed-7708164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77081642020-12-02 Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy Takekuma, Munetaka Takahashi, Fumiaki Mabuchi, Seiji Kudaka, Wataru Horie, Koji Ikeda, Mariko Shikama, Ayumi Mitsuhashi, Akira Nagao, Shoji Suzuki, Shiro Mizuno, Mika Nishio, Shin Tokunaga, Hideki Ota, Yukinobu Kasamatsu, Takahiro Kitagawa, Ryo Toita, Takafumi Kobayashi, Hiroaki Ishikawa, Mitsuya Yaegashi, Nobuo BMC Cancer Research Article BACKGROUND: The aim of the current study was to evaluate oncologic outcomes of patients who were treated with salvage hysterectomy (HT), compared to systemic chemotherapy (CT) for persistent cervical cancer after definitive radiotherapy (RT)/ concurrent chemoradiotherapy (CCRT). METHODS: Patients with persistent cervical cancer treated with definitive RT/CCRT at 35 institutions from 2005 to 2014 were reviewed retrospectively (n = 317). Those who underwent a HT for persistent cervical cancer after definitive RT/CCRT were matched with propensity scores for patients who underwent systemic CT. Oncologic outcomes between the two groups using a propensity score matched–cohort analysis were compared. RESULTS: A total of 142 patients with persistent cervical cancer after definitive RT/CCRT were included after matching (HT: 71, systemic CT: 71). All background factors between HT and CT groups were well balanced. Median overall survival was 3.8 and 1.5 years in the HT and CT groups, respectively (p = 0.00193, hazards ratio [HR] 0.41, 95% confidence interval [CI] 0.23–0.73), Increasing residual tumor size was significantly associated with a high incomplete resection rate (p = 0.016, Odds Ratio 1.11, 95%CI 1.02–1.22). Severe late adverse events occurred in 7 patients (9.9%) in the HT cohort. CONCLUSION: The current study demonstrated that, when compared to systemic CT, the adoption of salvage HT for patients with persistent cervical cancer after definitive RT/CCRT reduced mortality rate by about 60%. This indicates that salvage HT could be curative treatment for those patients. Further prospective clinical trials with regard to salvage HT after RT/CCRT are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-020-07672-w. BioMed Central 2020-11-30 /pmc/articles/PMC7708164/ /pubmed/33256667 http://dx.doi.org/10.1186/s12885-020-07672-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Takekuma, Munetaka
Takahashi, Fumiaki
Mabuchi, Seiji
Kudaka, Wataru
Horie, Koji
Ikeda, Mariko
Shikama, Ayumi
Mitsuhashi, Akira
Nagao, Shoji
Suzuki, Shiro
Mizuno, Mika
Nishio, Shin
Tokunaga, Hideki
Ota, Yukinobu
Kasamatsu, Takahiro
Kitagawa, Ryo
Toita, Takafumi
Kobayashi, Hiroaki
Ishikawa, Mitsuya
Yaegashi, Nobuo
Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
title Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
title_full Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
title_fullStr Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
title_full_unstemmed Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
title_short Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
title_sort propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708164/
https://www.ncbi.nlm.nih.gov/pubmed/33256667
http://dx.doi.org/10.1186/s12885-020-07672-w
work_keys_str_mv AT takekumamunetaka propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT takahashifumiaki propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT mabuchiseiji propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT kudakawataru propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT horiekoji propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT ikedamariko propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT shikamaayumi propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT mitsuhashiakira propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT nagaoshoji propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT suzukishiro propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT mizunomika propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT nishioshin propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT tokunagahideki propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT otayukinobu propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT kasamatsutakahiro propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT kitagawaryo propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT toitatakafumi propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT kobayashihiroaki propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT ishikawamitsuya propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy
AT yaegashinobuo propensityscorematchedanalysisofsystemicchemotherapyversussalvagehysterectomyforpersistentcervicalcancerafterdefinitiveradiotherapyconcurrentchemoradiotherapy